Thanks to our fans and followers, Arthritis Broadcast Network’s 2018 #CRArthritis Facebook and Twitter Live event reached over 94,205 people to date!
We did it! The Arthritis Broadcast Network (ABN) #CRArthritis Facebook and Twitter Live event at the Canadian Rheumatology Association (CRA) Annual Scientific Meeting and Arthritis Health Professions Association (AHPA) Annual Meeting conducted a total of 39 interviews (7 more than last year) in a little over 48 hours. Thank you to all of our interviewers, interviewees, and online audience who participated in the event. Because of you, the #CRArthritis event have informed and educated over 94,205 people to date. We’d say that’s an unqualified success, and you were a central part of making it happen – thank you!
ACE has carefully monitored the research on biologic use during pregnancy in response to the many ACE members who are thinking of starting a family and have concerns about continuing their medications.
We have previously reported on the study by Dr. Mary De Vera, Assistant Professor at the University of British Columbia’s Faculty of Pharmaceutical Sciences, and her team on “Patterns of medication use before, during, and after pregnancy among women with systemic lupus erythematosus: A population-based study”.
Dr. De Vera’s team assessed the use of medications in pregnant women with lupus in British Columbia. Most pregnancy trimesters in the study were exposed to hydroxychloroquine and/or chloroquine (41 to 45% of exposed pregnancy trimesters). The research observed an increase in glucocorticosteroid (like prednisone) exposures during pregnancy, as well as post-delivery. Findings emphasized the importance of counseling women regarding childbearing decisions as well as the need for evaluation of the risk-benefit profiles of medications in pregnancy.